ArticleCureus2025
Evolution of Anti-citrullinated Protein Antibodies in Rheumatoid Arthritis Patients Under Disease-Modifying Therapy: A Prospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The primary objective of our study was to describe the variation of anti-citrullinated protein antibodies (ACPA) antibody levels in patients with rheumatoid arthritis (RA) under disease-modifying therapy. The secondary objectives were to evaluate the variation of ACPA levels according to disease activity and to determine the characteristics of patients who have negative ACPA. Methods It was a prospective study including patients with ACPA-positive RA treated with disease-modifying antirheumatic drugs (DMARDs) and having a Disease Activity Score (DAS) greater than 2.6, indicating at least low disease activity or higher. A medical checkup including a clinical evaluation, an inflammatory test, and a measurement of ACPA levels using the enzyme-linked immunosorbent assay (ELISA) was performed for each patient at M0, M6, and M12. Two groups were defined: the rituximab (RTX) group, consisting of patients treated with RTX, and the no-RTX group, which included patients receiving other therapies, such as tumor necrosis factor inhibitors (TNFi) and interleukin 6 inhibitors (anti-IL6) or conventional disease-modifying antirheumatic drugs (csDMARDs). Results Ninety ACPA-positive RA patients were included. Seventy-seven (85.6%) were female and the mean age was 54.96 ± 13.13 years. The median disease duration was 11 years, and the baseline Disease Activity Score 28-C-reactive protein (DAS28-CRP) was 4.35 ± 0.99. Forty-eight (53.3%) of patients were already on RTX. The median ACPA level at baseline was 186 IU/ml (74-200), showing a significant decline over time (M0: 186 (74-200); M6: 111 (59-195); M12: 95 (45-195); p<0.001). This reduction was significant in the RTX group (ACPA M0: 191 (70-200); ACPA M6: 96 (33-195); ACPA M12: 75 (17-147); p<0.001) but not in the no-RTX group (ACPA M0: 156 (68-200); ACPA M6: 121 (70-195); ACPA M12: 175 (67-200); p=0.26). At M12, 27 (30%) patients achieved remission based on the DAS28 score. Their median ACPA level was 157 IU/ml (75-200) at baseline, which significantly decreased over time (p<0.001). When analyzing the delta ACPA, it was significantly larger in the RTX group (p<0.001). Conclusion In this real-life study, ACPA antibody levels decreased significantly in RA patients who had received RTX. This could suggest the possibility of achieving immunological remission with biotherapy, more specifically with RTX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.